Literature DB >> 24996975

Orphan drug designation for pracinostat, volasertib and alvocidib in AML.

Prithviraj Bose1, Steven Grant2.   

Abstract

Entities:  

Keywords:  AML; Alvocidib; Flavopiridol; Pracinostat; Rational combinations; Volasertib

Mesh：

Substances：

Year:  2014        PMID： 24996975     DOI： 10.1016/j.leukres.2014.06.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  14 in total

Review 1.  Treatment of Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Prithviraj Bose; Pankit Vachhani; Jorge E Cortes
Journal:  Curr Treat Options Oncol       Date:  2017-03

2.  The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Authors:  Liang Zhou; Shuang Chen; Yu Zhang; Maciej Kmieciak; Yun Leng; Lihong Li; Hui Lin; Kathryn A Rizzo; Catherine I Dumur; Andrea Ferreira-Gonzalez; Mohamed Rahmani; Lawrence Povirk; Sri Chalasani; Allison J Berger; Yun Dai; Steven Grant
Journal:  Blood       Date:  2016-02-05       Impact factor: 22.113

3.  Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.

Authors:  Wenxiu Qi; Wenbo Zhang; Holly Edwards; Roland Chu; Gerard J Madlambayan; Jeffrey W Taub; Zhihong Wang; Yue Wang; Chunhuai Li; Hai Lin; Yubin Ge
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.

Authors:  Beata Holkova; Danielle Shafer; Victor Yazbeck; Sandeep Dave; Prithviraj Bose; Mary Beth Tombes; Ellen Shrader; Wen Wan; Dipankar Bandyopadhyay; Caryn Weir; Elizabeth B Collins; Amanda Garnett; Maciej Kmieciak; John D Roberts; Guillermo Garcia-Manero; Steven Grant
Journal:  Leuk Lymphoma       Date:  2020-12-28

5.  Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.

Authors:  Yogesh A Sonawane; Margaret A Taylor; John Victor Napoleon; Sandeep Rana; Jacob I Contreras; Amarnath Natarajan
Journal:  J Med Chem       Date:  2016-06-03       Impact factor: 7.446

Review 6.  Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.

Authors:  Elisabetta Fratta; Barbara Montico; Aurora Rizzo; Francesca Colizzi; Luca Sigalotti; Riccardo Dolcetti
Journal:  Oncotarget       Date:  2016-08-30

7.  Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.

Authors:  Chengyin Min; Nathan Moore; Jeffrey R Shearstone; Steven N Quayle; Pengyu Huang; John H van Duzer; Matthew B Jarpe; Simon S Jones; Min Yang
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

Review 8.  Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.

Authors:  Younguk Sun; Bo-Rui Chen; Aniruddha Deshpande
Journal:  Front Oncol       Date:  2018-02-23       Impact factor: 6.244

Review 9.  Rational Combinations of Targeted Agents in AML.

Authors:  Prithviraj Bose; Steven Grant
Journal:  J Clin Med       Date:  2015-04-10       Impact factor: 4.964

10.  A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.

Authors:  L Zhou; Y Zhang; S Chen; M Kmieciak; Y Leng; H Lin; K A Rizzo; C I Dumur; A Ferreira-Gonzalez; Y Dai; S Grant
Journal:  Leukemia       Date:  2014-10-06       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.